DWA
TVRD

Dorsey Wright & Associates’s Tvardi Therapeutics TVRD Stock Holding History

Dorsey Wright & Associates’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-16
Closed -$10K – 363
2019
Q3 		$10K Hold
16
– – ﹤0.01% 264
2019
Q2 		$12K Buy
16
+4
+33% +$2.81K ﹤0.01% 218
2019
Q1 		$8K Sell
12
-12
-50% -$7.18K ﹤0.01% 238
2018
Q4 		$11K Buy
+24
New +$15.5K ﹤0.01% 261

Other funds holding TVRD

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Dorsey Wright & Associates's TVRD Position: Q4 2019 in Review

Dorsey Wright & Associates sold out of Tvardi Therapeutics (TVRD) in Q4 2019, closing a stake of 16 shares — an estimated $10K sold.

Dorsey Wright & Associates first reported a position in TVRD in Q4 2018 and held it in 4 quarters. The position peaked at $12K in Q2 2019. 151 funds tracked by Wall St. Rank hold TVRD as of Q4 2019.

  • Dorsey Wright & Associates reported no remaining Tvardi Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Dorsey Wright & Associates sold 16 Tvardi Therapeutics shares in Q4 2019, an estimated $10K.
  • Dorsey Wright & Associates first reported a position in Tvardi Therapeutics in Q4 2018 and held it in 4 quarters.
  • Dorsey Wright & Associates's Tvardi Therapeutics position peaked at $12K in Q2 2019.
  • 151 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2019.

Based on Dorsey Wright & Associates's 13F filing for Q4 2019, filed 31 Jan 2020.